AMNEAL PHARMACEUTICALS, INC.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | $2.61B | $232.0M | $151.2M |
| FY2020 | $2.74B | $303.3M | $341.4M |
| FY2021 | $2.68B | $360.3M | $247.8M |
| FY2022 | $2.59B | $298.4M | $26.0M |
| FY2023 | $2.39B | $19.8M | $91.5M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | $2.61B | $232.0M | $151.2M |
| FY2020 | $2.74B | $303.3M | $341.4M |
| FY2021 | $2.68B | $360.3M | $247.8M |
| FY2022 | $2.59B | $298.4M | $26.0M |
| FY2023 | $2.39B | $19.8M | $91.5M |